Blood Centers of America members account for over 30 percent of
transfusions in the U.S.
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ: CERS) and Blood Centers of America (BCA)
announced today that they have entered into an agreement with Cerus as a
BCA preferred supplier.
The 5 year agreement calls for BCA to actively promote the INTERCEPT
Blood System for platelets and plasma to nearly 50 member blood centers,
with a commitment for adoption by member centers representing a minimum
of 50% of the BCA aggregate volume.
“Our U.S. customer base already includes contracts with several
individual BCA members,” commented William “Obi” Greenman, Cerus’
president and chief executive officer. “This significant agreement
provides Cerus with the ability to serve BCA’s extensive blood center
membership more efficiently, and provides the independent blood centers
that make up BCA’s member base with the ability to implement the
INTERCEPT Blood System into their operations more quickly and cost
effectively.”
“The safety of the U.S. blood supply is dependent upon ensuring that we
use technology to combat emerging and potentially unknown pathogens that
could put patients at risk for transfusion-transmitted infections,” said
Bill Block, BCA’s president and chief executive officer. “We believe
that this agreement provides incentives and resources to help make it
easier for BCA members to adopt the INTERCEPT Blood System as their new
standard in blood transfusion safety.”
ABOUT BCA
BCA is a member-owned organization comprised of independent blood
centers throughout North America that account for more than 30 percent
of the U.S. blood supply, distributing over 632,000 platelet and
1,000,000 plasma units to 2,000 hospitals annually. Along with their
core business of providing a substantial portion of the blood supply,
BCA members provide other services including patient blood management,
transfusion services, immunohematology testing, therapeutic apheresis,
and tissue and cord blood banking. In addition, BCA members provide a
variety of human blood products, cells and tissues to the therapeutic,
diagnostic, and cell therapy industries. You can find more information
regarding Blood Centers of America at http://bca.coop.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for more information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160309005460/en/
Source: Cerus Corporation